Brokerages Set Masimo Corporation (NASDAQ:MASI) Target Price at $194.60

Masimo Corporation (NASDAQ:MASI) has received a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $194.60.

A number of equities analysts recently weighed in on the stock. Piper Sandler lifted their price objective on shares of Masimo from $200.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 6th. Weiss Ratings restated a “sell (d)” rating on shares of Masimo in a research note on Saturday, September 27th. BTIG Research reaffirmed a “buy” rating and issued a $198.00 target price on shares of Masimo in a report on Thursday, September 11th. Wall Street Zen cut shares of Masimo from a “buy” rating to a “hold” rating in a report on Monday. Finally, Zacks Research upgraded shares of Masimo from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, September 3rd.

Insider Buying and Selling at Masimo

In other Masimo news, Director William R. Jellison acquired 3,000 shares of the company’s stock in a transaction that occurred on Monday, August 11th. The shares were purchased at an average price of $145.98 per share, with a total value of $437,940.00. Following the completion of the acquisition, the director directly owned 4,790 shares of the company’s stock, valued at approximately $699,244.20. The trade was a 167.60% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 9.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Masimo

A number of institutional investors and hedge funds have recently made changes to their positions in MASI. Twin Tree Management LP acquired a new stake in shares of Masimo in the first quarter valued at about $29,000. MAI Capital Management lifted its position in shares of Masimo by 176.7% during the 2nd quarter. MAI Capital Management now owns 202 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 129 shares during the period. Farther Finance Advisors LLC boosted its stake in shares of Masimo by 128.9% during the 1st quarter. Farther Finance Advisors LLC now owns 206 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 116 shares in the last quarter. Hilltop National Bank purchased a new stake in shares of Masimo during the 2nd quarter worth approximately $37,000. Finally, Anderson Financial Strategies LLC acquired a new stake in shares of Masimo in the 1st quarter worth approximately $49,000. 85.96% of the stock is owned by institutional investors and hedge funds.

Masimo Stock Performance

NASDAQ MASI opened at $147.29 on Friday. The firm has a market cap of $8.00 billion, a P/E ratio of -17.29 and a beta of 1.28. Masimo has a 52-week low of $132.67 and a 52-week high of $194.88. The business’s 50-day moving average price is $146.78 and its 200 day moving average price is $155.79. The company has a quick ratio of 1.61, a current ratio of 2.14 and a debt-to-equity ratio of 0.57.

Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Tuesday, August 5th. The medical equipment provider reported $1.33 earnings per share for the quarter, topping analysts’ consensus estimates of $1.22 by $0.11. The company had revenue of $370.90 million during the quarter, compared to analysts’ expectations of $368.65 million. Masimo had a positive return on equity of 26.54% and a negative net margin of 24.85%.The firm’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same period last year, the firm earned $0.86 EPS. On average, equities research analysts expect that Masimo will post 4.1 earnings per share for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.